FF-10501-01 + azacitidine

FF-10501-01 + azacitidine is an investigational combination therapy being studied for previously untreated high-risk myelodysplastic syndrome (MDS). FF-10501-01 is a potent, selective competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme critical for de novo synthesis of guanine nucleotides, thus limiting nucleotide production needed for the proliferation of malignant hematopoietic cells. Azacitidine is a hypomethylating agent (HMA) that incorporates into DNA and RNA, leading to hypomethylation of DNA and cytotoxicity in abnormal hematopoietic cells. The combination is under investigation because FF-10501-01 can induce anti-proliferative and pro-apoptotic effects even in HMA-resistant cell lines, while azacitidine is a standard first-line therapy in high-risk MDS. The combo aims to enhance efficacy in MDS by dual targeting of nucleotide biosynthesis and DNA methylation. Clinical studies are ongoing in MDS, especially in patients with high-risk features or those ineligible for other therapies[1][3][4][2][5].